353 related articles for article (PubMed ID: 28980004)
41. Brentuximab vedotin: an anti-CD30 antibody-drug conjugate.
Bradley AM; Devine M; DeRemer D
Am J Health Syst Pharm; 2013 Apr; 70(7):589-97. PubMed ID: 23515511
[TBL] [Abstract][Full Text] [Related]
42. [Lymphomatoid papulosis type C or transition to CD30+-T-cell lymphoma? A difficult differential diagnosis].
Plettenberg H; Neumann NJ; Ruzicka T; Megahed M
Hautarzt; 2003 Apr; 54(4):366-8. PubMed ID: 12669213
[TBL] [Abstract][Full Text] [Related]
43. Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients.
Zinzani PL; Vitolo U; Viviani S; Corradini P; Motta G; Tani M; Cascavilla N; Hohaus S; Merli F; Argnani L; Broccoli A
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):404-8. PubMed ID: 25840816
[TBL] [Abstract][Full Text] [Related]
44. Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives.
Prince HM; Hutchings M; Domingo-Domenech E; Eichenauer DA; Advani R
Ann Hematol; 2023 Jan; 102(1):13-29. PubMed ID: 36512081
[TBL] [Abstract][Full Text] [Related]
45. Localized lymphomatoid papulosis: Unilesional lymphomatoid papulosis, regional lymphomatoid papulosis, and persistent agmination of lymphomatoid papulosis.
Magro CM; Mo JH; Telang G
Clin Dermatol; 2022; 40(6):622-638. PubMed ID: 35907581
[TBL] [Abstract][Full Text] [Related]
46. [Lymphomatoid papulosis in a 2 1/2-year-old boy].
Amann PM; Megahed M
Hautarzt; 2011 Nov; 62(11):807-9. PubMed ID: 22037883
[TBL] [Abstract][Full Text] [Related]
47. Population PK and Exposure-Response Relationships for the Antibody-Drug Conjugate Brentuximab Vedotin in CTCL Patients in the Phase III ALCANZA Study.
Suri A; Mould DR; Liu Y; Jang G; Venkatakrishnan K
Clin Pharmacol Ther; 2018 Nov; 104(5):989-999. PubMed ID: 29377077
[TBL] [Abstract][Full Text] [Related]
48. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.
Horwitz SM; Scarisbrick JJ; Dummer R; Whittaker S; Duvic M; Kim YH; Quaglino P; Zinzani PL; Bechter O; Eradat H; Pinter-Brown L; Akilov OE; Geskin L; Sanches JA; Ortiz-Romero PL; Weichenthal M; Fisher DC; Walewski J; Trotman J; Taylor K; Dalle S; Stadler R; Lisano J; Bunn V; Little M; Prince HM
Blood Adv; 2021 Dec; 5(23):5098-5106. PubMed ID: 34507350
[TBL] [Abstract][Full Text] [Related]
49. Phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphomas and lymphoproliferative disorders.
Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 5):12-4. PubMed ID: 24852791
[No Abstract] [Full Text] [Related]
50. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders.
Vonderheid EC; Sajjadian A; Kadin ME
J Am Acad Dermatol; 1996 Mar; 34(3):470-81. PubMed ID: 8609262
[TBL] [Abstract][Full Text] [Related]
51. Brentuximab vedotin for treatment of relapsed or refractory malignant lymphoma: results of a systematic review and meta-analysis of prospective studies.
Chen R; Wang F; Zhang H; Chen B
Drug Des Devel Ther; 2015; 9():2277-83. PubMed ID: 25945039
[TBL] [Abstract][Full Text] [Related]
52. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
Younes A; Santoro A; Shipp M; Zinzani PL; Timmerman JM; Ansell S; Armand P; Fanale M; Ratanatharathorn V; Kuruvilla J; Cohen JB; Collins G; Savage KJ; Trneny M; Kato K; Farsaci B; Parker SM; Rodig S; Roemer MG; Ligon AH; Engert A
Lancet Oncol; 2016 Sep; 17(9):1283-94. PubMed ID: 27451390
[TBL] [Abstract][Full Text] [Related]
53. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older.
Forero-Torres A; Holkova B; Goldschmidt J; Chen R; Olsen G; Boccia RV; Bordoni RE; Friedberg JW; Sharman JP; Palanca-Wessels MC; Wang Y; Yasenchak CA
Blood; 2015 Dec; 126(26):2798-804. PubMed ID: 26377597
[TBL] [Abstract][Full Text] [Related]
54. Brentuximab vedotin for treatment of systemic T-cell lymphoma.
Chihara D; Oki Y
Expert Opin Biol Ther; 2014 Oct; 14(10):1519-26. PubMed ID: 25200691
[TBL] [Abstract][Full Text] [Related]
55. Brentuximab-vedotin in combination with cyclophosphamide, doxorubicin, prednisolone for the treatment of aggressive CD30-positive cutaneous T-cell lymphomas.
Ribereau-Gayon E; Donzel M; Pham F; Romain-Scelle N; Perier-Muzet M; Balme B; Traverse-Glehen A; Ghesquières H; Dalle S
Leuk Lymphoma; 2023; 64(8):1424-1432. PubMed ID: 37255021
[TBL] [Abstract][Full Text] [Related]
56. Proapoptotic and antiapoptotic markers in cutaneous T-cell lymphoma skin infiltrates and lymphomatoid papulosis.
Nevala H; Karenko L; Vakeva L; Ranki A
Br J Dermatol; 2001 Dec; 145(6):928-37. PubMed ID: 11899146
[TBL] [Abstract][Full Text] [Related]
57. Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial.
Kim SJ; Yoon DH; Kim JS; Kang HJ; Lee HW; Eom HS; Hong JY; Cho J; Ko YH; Huh J; Yang WI; Park WS; Lee SS; Suh C; Kim WS
Cancer Res Treat; 2020 Apr; 52(2):374-387. PubMed ID: 31476851
[TBL] [Abstract][Full Text] [Related]
58. [Brentuximab vedotin treatment in patients with relapsed or refractory Hodgkin lymphoma. A Hungarian retrospective study].
Molnár Z; Pinczés LI; Piukovics K; Istenes I; Wolf K; Csukly Z; Szomor Á; Illés Á; Miltényi Z
Orv Hetil; 2017 Oct; 158(41):1630-1634. PubMed ID: 29025292
[TBL] [Abstract][Full Text] [Related]
59. Lymphomatoid Papulosis With a Unique T Follicular Helper-Like Phenotype.
Tran J; Duvic M; Torres-Cabala CA
Am J Dermatopathol; 2020 Oct; 42(10):776-779. PubMed ID: 32568843
[TBL] [Abstract][Full Text] [Related]
60. Lymphomatoid papulosis: Treatment response and associated lymphomas in a study of 180 patients.
Wieser I; Oh CW; Talpur R; Duvic M
J Am Acad Dermatol; 2016 Jan; 74(1):59-67. PubMed ID: 26518172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
